Sai Parenteral's (BOM:544742) PE Ratio: 1,521.26 (As of Aug. 09, 2026) — 1162% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544742 Sai Parenteral's Ltd BOM:544742
14 GF Score
Price ₹568.95
! 7 Warning Signs
View Full Analysis

What is Sai Parenteral's PE Ratio?

Sai Parenteral's BOM:544742 +5.09% 14 PE Ratio is 1,521.26 as of Aug. 09, 2026, which is 1162% above its 10-year median of 120.55. GuruFocus rates BOM:544742 with a GF Score™ of 14/100. The stock has 7 warning signs investors should review.

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2026-08-09), Sai Parenteral's's share price is ₹568.95. Sai Parenteral's's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0.37. Therefore, Sai Parenteral's's PE Ratio for today is 1,521.26.

Warning Sign:

Sai Parenteral's Ltd stock PE Ratio (=128.22) is close to 1-year high of 139.23.

During the past 3 years, Sai Parenteral's's highest PE Ratio was 1523.26. The lowest was 91.31. And the median was 120.55.

Sai Parenteral's's EPS (Diluted) for the six months ended in Sep. 2025 was ₹0.37. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0.37.

As of today (2026-08-09), Sai Parenteral's's share price is ₹568.95. Sai Parenteral's's EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0.37. Therefore, Sai Parenteral's's PE Ratio without NRI ratio for today is 1,521.26.

During the past 3 years, Sai Parenteral's's highest PE Ratio without NRI was 1523.26. The lowest was 91.31. And the median was 120.55.

Sai Parenteral's's EPS without NRI for the six months ended in Sep. 2025 was ₹0.37. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0.37.

Sai Parenteral's's EPS (Basic) for the six months ended in Sep. 2025 was ₹0.37. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2025 was ₹0.37.

Back to Basics: PE Ratio


Sai Parenteral's  (BOM:544742) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Sai Parenteral's PE Ratio Related Terms


Sai Parenteral's PE Ratio Historical Data

* Premium members only.

The historical data trend for Sai Parenteral's's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Parenteral's PE Ratio Chart

Sai Parenteral's Annual Data
Trend Mar23 Mar24 Mar25
PE Ratio
N/A N/A N/A

Sai Parenteral's Semi-Annual Data
Mar23 Mar24 Mar25 Sep25
PE Ratio At Loss N/A N/A At Loss

BOM:544742 vs LLY, JNJ, ABBV: PE Ratio Comparison

For the Drug Manufacturers - General subindustry, Sai Parenteral's's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sai Parenteral's PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sai Parenteral's's PE Ratio distribution charts can be found below:

* The bar in red indicates where Sai Parenteral's's PE Ratio falls into.


BOM:544742
14GF Score
Sai Parenteral's Ltd BOM:544742
PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Parenteral's PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Sai Parenteral's's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=568.95/0.374
=1521.26

Sai Parenteral's's Share Price of today is ₹568.95.
For company reported semi-annually, Sai Parenteral's's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹0.37.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio →
What does a PE Ratio of 1,521.26 mean?
Sai Parenteral's (BOM:544742) has a PE Ratio of 1,521.26 as of Aug. 09, 2026. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Sai Parenteral's and its competitors. This is 1162% above median its historical median of 120.55. Over the past decade, Sai Parenteral's' PE Ratio has ranged from 91.31 to 1,523.26.
Is Sai Parenteral's' PE Ratio too high?
Sai Parenteral's' current PE Ratio of 1,521.26 is 1162% above median its 10-year median of 120.55. Over the past 10 years, this metric has ranged from a low of 91.31 to a high of 1,523.26. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' PE Ratio compare to LLY and JNJ?
Sai Parenteral's' PE Ratio of 1,521.26 can be compared against companies in the Drug Manufacturers industry. Historically, Sai Parenteral's' own PE Ratio has ranged from 91.31 to 1,523.26 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio for a Drug Manufacturers company?
A good PE Ratio depends on the Drug Manufacturers industry context. However, PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio mean?
A high PE Ratio can signal that a stock is expensive relative to its fundamentals. P/E ratio is the ratio of share price to a company's earnings per share. View historical data on Sai Parenteral's and its competitors. Sai Parenteral's's current PE Ratio is 1,521.26, which is 1162% above median its own 10-year median of 120.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (BOM:544742) has a current PE Ratio of 1,521.26. The current PE Ratio is 1,521.26, which is 1162% above median its 10-year median of 120.55. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio calculated?
PE Ratio is calculated from a company's financial statements. For Sai Parenteral's (BOM:544742), the current PE Ratio is 1,521.26 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Parenteral's Business Description

Other Exchanges SAIPARENT:India
Address Plot No 39, 5th floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, TG, IND, 500032
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score

Get the complete analysis for BOM:544742

PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹568.95
Price